Figure 3 | British Journal of Cancer

Figure 3

From: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

Figure 3

Kaplan–Meier analysis after the completion of treatment (18 months) with ZOL in RCC patients. (A) β-isomer of carboxy-terminal telopeptide of collagen I (β-CTX) and overall survival. Stratification was performed using ‘normal or abnormal baseline marker values’ against death. (B) β-CTX and overall survival. Stratification was performed using the cutoff point obtained from the ROC curves of ‘baseline values of biomarkers at the beginning of the study’ against death. (C) β-CTX and disease progression. Stratification was performed using ‘normal or abnormal baseline marker values’ against death. (D) β-CTX and disease progression. Stratification was performed using the cutoff point obtained from the ROC curves of ‘baseline values of biomarkers at the beginning of the study’ against death. (E) Bone alkaline phosphatase (BALP) and new SRE. Stratification was performed using the cutoff point obtained from the ROC curves of ‘baseline values of biomarkers at the beginning of the study’ against death.

Back to article page